STEVENSON, Md., Jan. 25, 2016 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Florida on behalf of purchasers of ERBA Diagnostics, Inc. (NYSE MKT:ERB) (“ERBA” or the “Company”) securities during the period between April 14, 2014 and November 23, 2015, inclusive (the “Class Period”). Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until February 1, 2016 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in ERBA securities purchased on or after April 14, 2014 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company securities during the Class Period. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company lacked adequate controls over financial reporting such that its financial statements were materially false and misleading.
According to the complaint, following the Company’s November 20, 2015 disclosure that the Company’s previously issued financial statements for each of the years ended December 31, 2014 and 2013 and for each of the interim periods ended March 31, 2015 and June 30, 2015 should no longer be relied upon and that the Company intended to restate its financial statements for those periods, the value of ERBA’s shares declined significantly.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Italy Fines Apple €98.6 Million Over App Store Dominance
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 



